Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Politics

RFK Jr cancels $500 million in mRNA research, HHS to prioritize ‘safer’ vaccine alternatives

by admin August 6, 2025
August 6, 2025
RFK Jr cancels $500 million in mRNA research, HHS to prioritize ‘safer’ vaccine alternatives

A total of 22 mRNA vaccine development contracts totaling roughly $500 million have been canceled, the Department of Health and Human Services (HHS) announced Tuesday.

The mRNA investments were part of the government’s Biomedical Advanced Research and Development Authority (BARDA), a division of HHS that drives some of the country’s most advanced scientific research, such as the development of vaccines, drugs and other tools to fight national health threats. The termination of the 22 BARDA contracts follows a several-weeks-long internal review to determine a path forward when it comes to these investments.

‘We reviewed the science, listened to the experts, and acted,’ HHS Secretary Robert F. Kennedy Jr. said Tuesday. ‘BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.’

In a short video explaining the move, Kennedy said the benefits simply do not outweigh the risks associated with mRNA vaccines. 

Kennedy went on to point out that not only do mRNA vaccines – as shown during the COVID-19 pandemic – not perform well against viruses that infect the upper respiratory tract, but they also do not defend against mutations of the viruses they are intended to go after.

‘This dynamic drives a phenomena called anogenic shift, meaning that the vaccine paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine,’ Kennedy said in the video.

For example, the HHS secretary pointed to the omicron variant of the COVID-19 virus, which infected many millions, including those who had been vaccinated against COVID. 

‘A single mutation can make mRNA vaccines ineffective,’ Kebbedy added, noting that the same risks also apply to the flu virus. 

The move to cancel the mRNA contracts under BARDA will not entirely cancel all mRNA vaccine research done by the government, a source familiar with the move indicated. In addition to allowing some final-stage contracts to run their course to completion in an effort to preserve prior taxpayer investments, ongoing mRNA research at the National Institutes of Health (NIH) will not be impacted by this latest move. 

Meanwhile, in lieu of the terminated mRNA research and investments at BARDA, HHS will focus on ‘safer, broader vaccine strategies,’ Kennedy indicated.

‘To replace the troubled mRNA programs, we’re prioritizing the development of safer, broader vaccine strategies like whole virus vaccines and novel platforms that don’t collapse when viruses mutate,’ Kennedy said in his video explanation about the terminated mRNA investments.

During the video, Kennedy reiterated his support for ‘safe, effective vaccines’ for any American who wants them.

‘That’s why we’re moving beyond the limitations of mRNA for respiratory viruses and investing in better solutions.’

This post appeared first on FOX NEWS

previous post
Brazil’s ex-president and major Trump ally Bolsonaro placed on house arrest
next post
Michelle Obama celebrates Barack as ‘coolest guy’ on his birthday after the pair joked about divorce rumors

Related Posts

Saudi Arabia contradicts Trump, vows no ties with...

February 5, 2025

Trump eyes lifting sanctions, potential sale of prized...

March 22, 2025

Rubio heads to Panama, Latin America to pursue...

February 2, 2025

Panama eliminates charge fees for U.S. government vessels...

February 6, 2025

World leaders back Zelenskyy following Trump, Vance Oval...

March 1, 2025

USAID instructions for fired employees gives them 15...

February 26, 2025

Vance breaks key tie after Senate fails to...

May 1, 2025

Trump to sign order instructing DOGE to massively...

February 12, 2025

‘Not constitutional’: Congress evokes new War Powers Resolution...

June 22, 2025

Netanyahu will reportedly hold a security meeting at...

February 16, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 5

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved